Homology Medicines, Inc. (FIXX) Misses Q2 EPS by 11c

Homology Medicines, Inc. (NASDAQ: FIXX) reported Q2 EPS of ($0.61), $0.11 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $354 thousand versus the consensus estimate of $864.4 thousand.

For earnings history and earnings-related data on Homology Medicines, Inc. (FIXX) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Goldman Sachs Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance